
Semaglutide
by Novo Nordisk
Average 21% body weight loss — the gold standard in medically supervised weight loss
21%
Average body weight loss
STEP 1 trial, NEJM 2021
86%
Patients lost ≥5% body weight
STEP 1 trial, NEJM 2021
20%
Reduction in cardiovascular risk
SELECT trial, NEJM 2023
68 weeks
Duration of pivotal clinical trial
STEP 1 trial, NEJM 2021
Semaglutide mimics the hormone GLP-1, which is naturally released after eating. It works by slowing gastric emptying, reducing appetite signals in the brain, and improving insulin sensitivity — leading to significant, sustained caloric reduction without the feeling of deprivation.
Always follow your prescribing physician's specific instructions. The schedule below is a general guide.
Initiation dose — helps your body adjust, not a therapeutic dose
First escalation — most patients notice appetite reduction
Second escalation — significant weight loss typically begins
Third escalation — continued dose optimisation
Full maintenance dose — target weekly injection for long-term management
Seek immediate medical attention if you experience any serious adverse effects.
Starting from
$99.00
Reviewed by a licensed US physician
Up to 22.5% body weight loss — the most effective weight loss medication in clinical history
The affordable liraglutide option — same proven GLP-1 mechanism as Saxenda at a lower cost
Effective oral appetite control for patients who prefer tablets over injections
A licensed US physician will review your consultation, answer all your questions, and prescribe if you're eligible — all from the comfort of home.
No commitment · Reviewed within 24 hours · HIPAA-compliant